行情

IDXG

IDXG

Interpace Biosciences
NASDAQ

实时行情|Nasdaq Last Sale

10.29
+1.20
+13.16%
盘后: 10.50 +0.22 +2.09% 19:37 02/20 EST
开盘
9.08
昨收
9.09
最高
10.37
最低
9.08
成交量
14.95万
成交额
--
52周最高
10.40
52周最低
3.810
市值
3,928.46万
市盈率(TTM)
-0.1710
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

IDXG 新闻

  • 《消费者报告》首次将特斯拉Model 3列为"首选车型"
  • 新浪美股.7小时前
  • 低利率的大背景下 市政债券或成“新贵”
  • 新浪财经-自媒体综合.8小时前
  • 巴以双方解除农产品贸易禁令
  • 新华网.9小时前
  • 联储二号人物给交易员"泼冷水" 这次市场共识又错了?
  • FX168.9小时前

更多

所属板块

管理型医疗保健
-1.47%
医疗保健提供商与服务
-1.06%

热门股票

名称
价格
涨跌幅

IDXG 简况

Interpace Biosciences, Inc., formerly Interpace Diagnostics Group, Inc., is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management. The Company operates through molecular diagnostics segment. It offers molecular tests, such as PancraGen, which is a pancreatic cyst molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its PathFinder platform; ThyGenX, which assesses thyroid nodules for risk of malignancy, and ThyraMIR, which assesses thyroid nodules risk of malignancy utilizing a gene expression assay. Through its molecular diagnostics business, it provides diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers, which are focused on early detection of cancer.
展开

Webull提供Interpace Biosciences Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。